KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Treasury Shares (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Treasury Shares for 5 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares rose 1253.71% year-over-year to $11.1 million, compared with a TTM value of $11.1 million through Dec 2025, up 1253.71%, and an annual FY2025 reading of $11.1 million, up 1253.71% over the prior year.
  • Treasury Shares was $11.1 million for Q4 2025 at Biocryst Pharmaceuticals, up from $8.7 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $11.1 million in Q4 2025 and bottomed at $813000.0 in Q1 2024.
  • Average Treasury Shares over 3 years is $4.3 million, with a median of $882000.0 recorded in 2025.
  • The sharpest move saw Treasury Shares tumbled 85.28% in 2024, then skyrocketed 1253.71% in 2025.
  • Year by year, Treasury Shares stood at $5.6 million in 2023, then crashed by 85.28% to $823000.0 in 2024, then surged by 1253.71% to $11.1 million in 2025.
  • Business Quant data shows Treasury Shares for BCRX at $11.1 million in Q4 2025, $8.7 million in Q3 2025, and $882000.0 in Q2 2025.